Alluvi, previously BI 4744, offers a promising advance in weight management therapy. This dual activator targeting both GLP-1 and GIP receptors demonstrates remarkable effectiveness in clinical assessments, potentially https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/